The Online Investor
Warner Chilcott Plc (New) (WCRX)

Warner Chilcott is a pharmaceutical company focused on the women's healthcare, gastroenterology, dermatology and urology segments of the pharmaceuticals market. Co.'s principal products include: ATELVIA for the treatment of postmenopausal osteoporosis; LOESTRIN 24 FE and LO LOESTRIN FE hormonal contraceptives for the prevention of pregnancy; ESTRACE vaginal cream for the treatment of vaginal and vulvar atrophy; ASACOL 400 mg for the treatment of mild to moderate ulcerative colitis and maintenance of remission; ASACOL HD (800 mg) for the treatment of moderately active ulcerative colitis; DORYX 150 mg, an oral adjunctive therapy for acne; and ENABLEX for the treatment of overactive bladder.
Company Name: 
Warner Chilcott Plc (New)
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree WCRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.89 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Warner Chilcott Plc (New) (WCRX) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.